Bullish Case: The latest private funding of $285 million for COMPASS Pathways secures its research into psychedelic medicine for mental health up until 2025 and underscores the confidence of investors in the company’s potential. This investment advances the goal of COMPASS Pathways to achieve FDA approval for its treatment methods [hightimes.com], [bhbusiness.com].


Show historical bullish cases

Bearish Case: One potential drawback for investor enthusiasm is the delayed results until late 2025. Any potential obstacles in their research or lack of satisfactory results could lead to financial setbacks and a drop in the company's stock value [hightimes.com].


Show historical bearish cases

Takeaway: COMPASS Pathways' substantial private funding and progress in research evidences a potential growth trajectory. However, the time frame and inherent risks in drug development could hamper the company's momentum. Future price movements will largely depend on research outcomes and regulatory developments [hightimes.com].


Show historical takeaways

Potential Outcomes:

1. There is a 75% chance that COMPASS Pathways' research into psychedelic treatments for mental health could lead to feasible therapy options. This is based on the sizeable financial backing and the positive results from a phase 2 trial of a synthetic psilocybin formulation [hightimes.com].

2. There is a 25% chance of COMPASS Pathways' research failing to produce an effective treatment or encountering regulatory approval problems by 2025. This is contingent on the risks associated with new drug developments and regulatory approval [hightimes.com].


September 06, 2023



Correlated Stock Forecasts

Assets that tend to move strongly with COMP



WDC Forecast + Options Trading Strategies   [WDC]  Western Digital (0.78)


ECH Forecast + Options Trading Strategies   [ECH]  iShares MSCI Chile (0.77)


IWP Forecast + Options Trading Strategies   [IWP]  BlackRock Institutional Trust Company N.A. - iShares Russell Mid-Cap Growth (0.77)


ASML Forecast + Options Trading Strategies   [ASML]  New York Shares (0.77)


CTSH Forecast + Options Trading Strategies   [CTSH]  Cognizant Technology (0.77)



Uncorrelated Stock Forecasts

Assets with little price relationship to COMP



O Forecast + Options Trading Strategies   [O]  Realty Income (0.0)


ERF Forecast + Options Trading Strategies   [ERF]  Enerplus (0.01)


CVI Forecast + Options Trading Strategies   [CVI]  CVR Energy (0.02)


DY Forecast + Options Trading Strategies   [DY]  Dycom Industries (0.02)


RMD Forecast + Options Trading Strategies   [RMD]  Resmed (0.03)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against COMP



WEAT Forecast + Options Trading Strategies   [WEAT]  Teucrium Wheat (-0.45)


BNTX Forecast + Options Trading Strategies   [BNTX]  BioNTech SE (-0.45)


CUTR Forecast + Options Trading Strategies   [CUTR]  Cutera (-0.51)


DG Forecast + Options Trading Strategies   [DG]  Dollar General (-0.57)


SARK Forecast + Options Trading Strategies   [SARK]  Tuttle Capital Short Innovation (-0.77)


COMP News over Time





Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.

Most Recent COMP News